Lineage Cell Therapeutics, Inc. (LCTX)
USD 0.5
(0.93%)
USD 0.5
(0.93%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -21.48 Million USD | 18.47% |
| 2022 | -26.35 Million USD | 31.66% |
| 2021 | -38.56 Million USD | -86.43% |
| 2020 | -20.68 Million USD | -74.9% |
| 2019 | -11.82 Million USD | 74.28% |
| 2018 | -45.99 Million USD | -130.23% |
| 2017 | -19.97 Million USD | -159.5% |
| 2016 | 33.57 Million USD | 171.44% |
| 2015 | -46.99 Million USD | -29.05% |
| 2014 | -36.41 Million USD | 17.03% |
| 2013 | -43.88 Million USD | -104.81% |
| 2012 | -21.42 Million USD | -29.73% |
| 2011 | -16.51 Million USD | -47.66% |
| 2010 | -11.18 Million USD | -117.43% |
| 2009 | -5.14 Million USD | -36.05% |
| 2008 | -3.78 Million USD | -162.89% |
| 2007 | -1.43 Million USD | 22.87% |
| 2006 | -1.86 Million USD | 10.11% |
| 2005 | -2.07 Million USD | 32.77% |
| 2004 | -3.08 Million USD | -77.11% |
| 2003 | -1.74 Million USD | 38.77% |
| 2002 | -2.84 Million USD | 22.24% |
| 2001 | -3.65 Million USD | 25.71% |
| 2000 | -4.92 Million USD | 10.13% |
| 1999 | -5.47 Million USD | -160.95% |
| 1998 | -2.1 Million USD | 30.0% |
| 1997 | -3 Million USD | -50.0% |
| 1996 | -2 Million USD | 16.67% |
| 1995 | -2.4 Million USD | -60.0% |
| 1994 | -1.5 Million USD | -25.0% |
| 1993 | -1.2 Million USD | -71.43% |
| 1992 | -700 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -5.76 Million USD | 11.95% |
| 2024 Q1 | -6.54 Million USD | -37.01% |
| 2023 Q1 | -4.4 Million USD | 33.19% |
| 2023 Q4 | -4.77 Million USD | 32.84% |
| 2023 Q2 | -5.22 Million USD | -18.73% |
| 2023 Q3 | -7.11 Million USD | -35.97% |
| 2023 FY | -21.48 Million USD | 18.47% |
| 2022 FY | -26.35 Million USD | 31.66% |
| 2022 Q3 | -6.11 Million USD | 38.64% |
| 2022 Q4 | -6.59 Million USD | -7.78% |
| 2022 Q1 | -8.29 Million USD | 71.38% |
| 2022 Q2 | -9.96 Million USD | -20.13% |
| 2021 Q3 | -7.82 Million USD | -63.39% |
| 2021 FY | -38.56 Million USD | -86.43% |
| 2021 Q4 | -28.99 Million USD | -270.57% |
| 2021 Q1 | -1.41 Million USD | -169.69% |
| 2021 Q2 | -4.78 Million USD | -238.14% |
| 2020 Q3 | -7.76 Million USD | -18.98% |
| 2020 FY | -20.68 Million USD | -74.9% |
| 2020 Q1 | -8.39 Million USD | -87.39% |
| 2020 Q4 | 2.03 Million USD | 126.19% |
| 2020 Q2 | -6.52 Million USD | 22.35% |
| 2019 Q1 | 39.31 Million USD | 187.45% |
| 2019 Q3 | -16.5 Million USD | 45.04% |
| 2019 Q4 | -4.48 Million USD | 72.84% |
| 2019 FY | -11.82 Million USD | 74.28% |
| 2019 Q2 | -30.03 Million USD | -176.4% |
| 2018 Q3 | 66.72 Million USD | 1683.04% |
| 2018 FY | -45.99 Million USD | -130.23% |
| 2018 Q1 | -63.54 Million USD | 11.66% |
| 2018 Q4 | -44.95 Million USD | -167.37% |
| 2018 Q2 | -4.21 Million USD | 93.37% |
| 2017 Q1 | 49.28 Million USD | 1071.0% |
| 2017 FY | -19.97 Million USD | -159.5% |
| 2017 Q4 | -71.93 Million USD | -602.3% |
| 2017 Q2 | -11.65 Million USD | -123.64% |
| 2017 Q3 | 14.32 Million USD | 222.92% |
| 2016 Q4 | -5.07 Million USD | -116.27% |
| 2016 Q1 | -17.11 Million USD | -27.47% |
| 2016 Q2 | 24.54 Million USD | 243.46% |
| 2016 Q3 | 31.19 Million USD | 27.09% |
| 2016 FY | 33.57 Million USD | 171.44% |
| 2015 Q1 | -10.16 Million USD | 3.79% |
| 2015 Q2 | -9.69 Million USD | 4.69% |
| 2015 Q4 | -13.42 Million USD | 1.48% |
| 2015 FY | -46.99 Million USD | -29.05% |
| 2015 Q3 | -13.62 Million USD | -40.6% |
| 2014 Q2 | -9.52 Million USD | -17.55% |
| 2014 Q3 | -8.26 Million USD | 13.15% |
| 2014 Q4 | -10.56 Million USD | -27.81% |
| 2014 Q1 | -8.09 Million USD | 58.7% |
| 2014 FY | -36.41 Million USD | 17.03% |
| 2013 Q3 | -9 Million USD | -19.25% |
| 2013 Q2 | -7.54 Million USD | 2.2% |
| 2013 Q1 | -7.71 Million USD | -27.91% |
| 2013 FY | -43.88 Million USD | -104.81% |
| 2013 Q4 | -19.61 Million USD | -117.84% |
| 2012 Q2 | -5.45 Million USD | -9.73% |
| 2012 Q1 | -4.97 Million USD | 7.23% |
| 2012 FY | -21.42 Million USD | -29.73% |
| 2012 Q3 | -4.95 Million USD | 9.15% |
| 2012 Q4 | -6.03 Million USD | -21.72% |
| 2011 Q3 | -3.73 Million USD | 12.63% |
| 2011 Q1 | -3.36 Million USD | -13.22% |
| 2011 Q2 | -4.27 Million USD | -27.24% |
| 2011 Q4 | -5.36 Million USD | -43.42% |
| 2011 FY | -16.51 Million USD | -47.66% |
| 2010 Q3 | -4.67 Million USD | -106.71% |
| 2010 Q1 | -1.31 Million USD | -192.37% |
| 2010 FY | -11.18 Million USD | -117.43% |
| 2010 Q2 | -2.25 Million USD | -72.24% |
| 2010 Q4 | -2.96 Million USD | 36.43% |
| 2009 Q1 | -1.51 Million USD | 2.99% |
| 2009 Q2 | -1.47 Million USD | 3.09% |
| 2009 Q4 | 1.42 Million USD | 139.74% |
| 2009 Q3 | -3.57 Million USD | -142.95% |
| 2009 FY | -5.14 Million USD | -36.05% |
| 2008 Q4 | -1.56 Million USD | -45.28% |
| 2008 Q1 | -476.04 Thousand USD | -45.67% |
| 2008 Q3 | -1.07 Million USD | -62.53% |
| 2008 Q2 | -662.78 Thousand USD | -39.23% |
| 2008 FY | -3.78 Million USD | -162.89% |
| 2007 Q4 | -326.79 Thousand USD | -53.07% |
| 2007 Q2 | -344.07 Thousand USD | 37.88% |
| 2007 Q1 | -553.86 Thousand USD | -46.31% |
| 2007 FY | -1.43 Million USD | 22.87% |
| 2007 Q3 | -213.49 Thousand USD | 37.95% |
| 2006 Q2 | -667.84 Thousand USD | -39.66% |
| 2006 Q4 | -378.55 Thousand USD | -11.33% |
| 2006 Q3 | -340.03 Thousand USD | 49.08% |
| 2006 Q1 | -478.18 Thousand USD | 2.38% |
| 2006 FY | -1.86 Million USD | 10.11% |
| 2005 FY | -2.07 Million USD | 32.77% |
| 2005 Q1 | -726.59 Thousand USD | -32.58% |
| 2005 Q2 | -442.73 Thousand USD | 39.07% |
| 2005 Q3 | -415.05 Thousand USD | 6.25% |
| 2005 Q4 | -489.87 Thousand USD | -18.02% |
| 2004 Q4 | -548.05 Thousand USD | -21.23% |
| 2004 Q1 | -1.64 Million USD | -174.7% |
| 2004 Q2 | -442.26 Thousand USD | 73.08% |
| 2004 Q3 | -452.06 Thousand USD | -2.21% |
| 2004 FY | -3.08 Million USD | -77.11% |
| 2003 Q1 | -751.12 Thousand USD | 3.26% |
| 2003 FY | -1.74 Million USD | 38.77% |
| 2003 Q3 | 362.02 Thousand USD | 147.96% |
| 2003 Q2 | -754.87 Thousand USD | -0.5% |
| 2003 Q4 | -598.09 Thousand USD | -265.21% |
| 2002 Q3 | -578.86 Thousand USD | 26.09% |
| 2002 Q4 | -776.47 Thousand USD | -34.14% |
| 2002 FY | -2.84 Million USD | 22.24% |
| 2002 Q1 | -706.4 Thousand USD | -13.57% |
| 2002 Q2 | -783.18 Thousand USD | -10.87% |
| 2001 Q2 | -1.12 Million USD | -17.68% |
| 2001 Q1 | -951.73 Thousand USD | 9.39% |
| 2001 Q3 | -903.36 Thousand USD | 19.34% |
| 2001 FY | -3.65 Million USD | 25.71% |
| 2001 Q4 | -622.02 Thousand USD | 31.14% |
| 2000 Q3 | -1.22 Million USD | 7.88% |
| 2000 FY | -4.92 Million USD | 10.13% |
| 2000 Q1 | -1.31 Million USD | 10.81% |
| 2000 Q2 | -1.32 Million USD | -0.74% |
| 2000 Q4 | -1.05 Million USD | 14.25% |
| 1999 Q2 | -1 Million USD | -25.0% |
| 1999 Q1 | -800 Thousand USD | 0.0% |
| 1999 FY | -5.47 Million USD | -160.95% |
| 1999 Q4 | -1.47 Million USD | 35.66% |
| 1999 Q3 | -2.3 Million USD | -130.0% |
| 1998 Q1 | -1.1 Million USD | -83.33% |
| 1998 FY | -2.1 Million USD | 30.0% |
| 1998 Q3 | -1.1 Million USD | -37.5% |
| 1998 Q2 | -800 Thousand USD | 27.27% |
| 1997 FY | -3 Million USD | -50.0% |
| 1997 Q1 | -500 Thousand USD | 37.5% |
| 1997 Q4 | -600 Thousand USD | 40.0% |
| 1997 Q3 | -1 Million USD | 0.0% |
| 1997 Q2 | -1 Million USD | -100.0% |
| 1996 Q2 | -500 Thousand USD | 16.67% |
| 1996 Q3 | -700 Thousand USD | -40.0% |
| 1996 Q4 | -800 Thousand USD | -14.29% |
| 1996 FY | -2 Million USD | 16.67% |
| 1996 Q1 | -600 Thousand USD | 0.0% |
| 1995 Q3 | -300 Thousand USD | 57.14% |
| 1995 Q4 | -600 Thousand USD | -100.0% |
| 1995 Q2 | -700 Thousand USD | -16.67% |
| 1995 Q1 | -600 Thousand USD | 0.0% |
| 1995 FY | -2.4 Million USD | -60.0% |
| 1994 Q1 | -300 Thousand USD | 25.0% |
| 1994 FY | -1.5 Million USD | -25.0% |
| 1994 Q3 | -500 Thousand USD | -25.0% |
| 1994 Q2 | -400 Thousand USD | -33.33% |
| 1994 Q4 | -600 Thousand USD | -20.0% |
| 1993 Q1 | -200 Thousand USD | 33.33% |
| 1993 Q3 | -300 Thousand USD | 0.0% |
| 1993 Q4 | -400 Thousand USD | -33.33% |
| 1993 FY | -1.2 Million USD | -71.43% |
| 1993 Q2 | -300 Thousand USD | -50.0% |
| 1992 Q2 | -200 Thousand USD | 0.0% |
| 1992 FY | -700 Thousand USD | 0.0% |
| 1992 Q4 | -300 Thousand USD | 0.0% |
| 1992 Q1 | -200 Thousand USD | 0.0% |
| 1992 Q3 | -300 Thousand USD | -50.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 25.813% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -148.911% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 68.881% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 55.988% |
| Azitra, Inc. | -11.28 Million USD | -90.415% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -181.451% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -191.107% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 26.458% |
| CEL-SCI Corporation | -32.36 Million USD | 33.615% |
| iBio, Inc. | -24.9 Million USD | 13.735% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | -8.664% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 6.346% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -41.568% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -122.884% |
| NanoViricides, Inc. | -8.29 Million USD | -159.05% |
| Oragenics, Inc. | -20.65 Million USD | -4.02% |
| BiomX Inc. | -26.16 Million USD | 17.895% |
| BiomX Inc. | -26.16 Million USD | 17.895% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 358.494% |
| Palatin Technologies, Inc. | -29.73 Million USD | 27.744% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 52.483% |